Primary tabs
Revisions allow you to track differences between multiple versions of your content, and revert back to older versions.
| Revision | Operations | |
|---|---|---|
| 10-30-23 by kaipe | current revision | |
| 10-26-23 by kaipe | ||
| 10-26-23 by kaipe | ||
| 10-26-23 by kaipe | ||
| 10-19-23 by kaipe | ||
| 10-4-23 by kaipe 10/4/23: Removed "meningitis" as a line item (discussed with empirical guideline working group), added caveat for patients where q6h may be considered | ||
| 02-17-22 by [email protected] | ||
| 07-26-21 by conan.macdougal... | ||
| 06-29-21 by [email protected] | ||
| 06-24-21 by conan.macdougal... | ||
| 06-24-21 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 08-12-20 by conan.macdougal... | ||
| 07-10-20 by [email protected] | ||
| 07-7-20 by [email protected] | ||
| 07-7-20 by [email protected] | ||
| 07-7-20 by [email protected] | ||
| 04-17-20 by ucsf_admin | ||
| 02-5-20 by ucsf_admin | ||
| 02-4-20 by ucsf_admin | ||
Dosing: Adult Antimicrobial Dosing, Non-dialysis
| Indication |
CrCl > 50 mL/min |
10 - 50 mL/min | < 10 mL/min |
|---|---|---|---|
| All indications |
2 g IV q8h* |
2 g IV q12h | 1 g IV q12h |
*2 g IV q6h may be considered for meningitis in select patients based on clinical judgement (e.g. obesity, young age, augmented renal clearance, etc), or in select resistant gram-negative infections in combination with ceftazidime-avibactam (infuse both over 3 hours).
If used in combination with ceftazidime-avibactam and dosing intervals are the same, simultaneous administration is preferred.
Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis
|
Indication |
Intermittent Hemodialysis |
Continuous Hemodialysis |
|---|---|---|
| All Indications | 2 g IV x1 now, then qPM | 2 g IV q12h |
Dialysis Notes
Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR < 10 mL/min. For detailed view of dialysis dosing and evidence, see Dosing in Hemodialysis document.
Aztreonam lacks cross-reactivity with most other beta-lactams; however, most patients who have a recorded beta-lactam allergy can receive another beta-lactam through screening, test dosing, or skin testing. See Inpatient Allergy Guidelines